Russo A - Search Results

1

Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.

Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Rolfo C, et al. Among authors: russo a. Curr Pharm Biotechnol. 2014;15(5):475-85. doi: 10.2174/1389201015666140519123219. Curr Pharm Biotechnol. 2014. PMID: 24846062 Review.

2

Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.

Russo A, Corsale S, Cammareri P, Agnese V, Cascio S, Di Fede G, Macaluso M, Bazan V. Russo A, et al. J Cell Physiol. 2005 Sep;204(3):742-9. doi: 10.1002/jcp.20357. J Cell Physiol. 2005. PMID: 15828025 Review.

3

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group. Russo A, et al. J Clin Oncol. 2005 Oct 20;23(30):7518-28. doi: 10.1200/JCO.2005.00.471. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172461 Review.

4

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

Russo A, Fratto ME, Bazan V, Schiró V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D. Russo A, et al. Expert Opin Ther Targets. 2007 Dec;11(12):1571-86. doi: 10.1517/14728222.11.12.1571. Expert Opin Ther Targets. 2007. PMID: 18020979 Review.

5

Hereditary ovarian cancer.

Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G. Russo A, et al. Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44. doi: 10.1016/j.critrevonc.2008.06.003. Epub 2008 Jul 24. Crit Rev Oncol Hematol. 2009. PMID: 18656380 Free article. Review.

6

Male breast cancer.

Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Ottini L, et al. Among authors: russo a. Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55. doi: 10.1016/j.critrevonc.2009.04.003. Epub 2009 May 7. Crit Rev Oncol Hematol. 2010. PMID: 19427229 Review.

7

Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.

Cascio S, Ferla R, D'Andrea A, Gerbino A, Bazan V, Surmacz E, Russo A. Cascio S, et al. Among authors: russo a. J Cell Physiol. 2009 Oct;221(1):189-94. doi: 10.1002/jcp.21843. J Cell Physiol. 2009. PMID: 19492417

8

Bortezomib: a new pro-apoptotic agent in cancer treatment.

Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S. Russo A, et al. Curr Cancer Drug Targets. 2010 Feb;10(1):55-67. doi: 10.2174/156800910790980250. Curr Cancer Drug Targets. 2010. PMID: 20088794

9

Anti-endothelin drugs in solid tumors.

Russo A, Bronte G, Rizzo S, Fanale D, Di Gaudio F, Gebbia N, Bazan V. Russo A, et al. Expert Opin Emerg Drugs. 2010 Mar;15(1):27-40. doi: 10.1517/14728210903571667. Expert Opin Emerg Drugs. 2010. PMID: 20102289 Free article. Review.

10

The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.

Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F. Russo A, et al. Oncology. 2009;77 Suppl 1:57-68. doi: 10.1159/000258497. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130433 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,458 results

Search Page